Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7735 ext. 287; fax: 301/402–0220; e-mail: CL21R@NIH.GOV.

Information about the patent applications and pertinent information not yet publicly described can be obtained under a Confidential Disclosure Agreement. Respondees interested in licensing the invention(s) will be required to submit an Application for License to Public Health Service Inventions.

SUPPLEMENTARY INFORMATION: As part of its continuing steroid synthesis program and its expanded mission, the Contraception and Reproductive Health Branch, Center for Population, National Institute of Child Health and Human Development, has developed several 21-substituted derivatives of progesterone for therapeutic applications as antiprogestational agents.

Preclinical evaluation of these steroids indicates greater antiprogestational activity and reduced antiglucocorticoid activity compared with mifepristone. These data and those derived from a number of endocrinological, reproductive and receptor binding studies are available for the process of due diligence. None of these data has been published. Radioimmunoassays for these steroids are being developed. No toxicological studies have been undertaken, but extensive safety studies have been performed on a similar antiprogestational agent.

Antiprogestational agents have a broad spectrum of potential therapeutic uses in gynecic medicine including cervical ripening, endometriosis, uterine fibroids, breast and endometrial cancer and postmenopausal hormone replacement therapy.

Applicants for licensing are encouraged to submit a research plan which encompasses the most extensive development for therapeutic use.

Dated: September 26, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97–26630 Filed 10–7–97; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel (SEP) meeting:

Name of SEP: NIAMS SEP Program Project Review.

Date: November 19, 1997.

Time: 8:00 a.m.-5:00 p.m.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Bethesda, Maryland 20815.

Contact Person: Aftab A. Ansari, Ph.D., Scientific Review Administrator, Natcher Building, 45 Center Drive, Rm 5AS25U, Bethesda, Maryland 20892–6500, Telephone: 301–594–4952.

Purpose/Agenda: To evaluate and review research grant applications.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The discussion of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. [93.846, Project Grants in Arthritis, Musculoskeletal and Skin Diseases Research], National Institutes of Health, HHS)

Dated: October 1, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH. [FR Doc. 97–26627 Filed 10–7–97; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Closed Meetings

Prusant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice of hereby given of the following National Institute of Child Health and Human Development Initial Review Group meetings:

Name of Subcommittee: Population Research Subcommittee.

Date: October 9-10, 1997.

Time: October 9–8:00 a.m.-5:00 p.m.; October 10–8:00 a.m.-adjournment.

Place: Bethesda Ramada Hotel, 8400 Wisconsin Avenue, Bethesda, Maryland 20814.

Contact Person: A.T. Gregoire, Ph.D., Scientific Review Administrator, DSR, 6100 Executive Boulevard, Room 5E01, Bethesda, Maryland 20892, Telephone: 301–496–1485.

Name of Subcommittee: Population Research Subcommittee.

Date: October 16, 1997.

Time: 8:00 a.m.-adjournment.

Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, Maryland 20814.

Contact Person: A.T. Gregoire, Ph.D., Scientific Review Administrator, DSR, 6100 Executive Boulevard, Room 5E01, Bethesda, Maryland 20892, Telephone: 301–496–1485.

This notice is being published less than 15 days prior to the above meetings due to the urgent need to meet timing limitations imposed by the review and funding cycle.

Name of Subcommittee: Mental Retardation Subcommittee.

Date: October 20, 1997.

Time: 8:00 a.m.-adjournment.

Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, Maryland 20814.

Contact Person: Norman Chang, Ph.D., Scientific Review Administrator, DSR, 6100 Executive Boulevard, Room 5E01, Bethesda, Maryland 20892, Telephone: 301–496–1485.

Name of Subcommittee: Maternal and Child Health Research Subcommittee.

Date: October 21–22, 1997.

Time: October 21–8:00 a.m.–5:00 p.m.; October 22–8:00 a.m.-adjournment.

Place: Holiday Inn-Silver Spring, 8777 Georgia Avenue, Silver Spring, Maryland 20910.

Contact Person: Gopal M. Bhatnagar, Ph.D., Scientific Review Administrator, DSR, 6100 Executive Boulevard, Room 5E01, Bethesda, Maryland 20892, Telephone: 301–496–1485.

Name of Subcommittee: Medical Rehabilitation Research Subcommittee.

Date: October 22–23, 1997.

Time: October 22–8:30 a.m.–5:00 p.m.; October 23–8:30 a.m.-adjournment.

Place: Holiday Inn-Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, Maryland. Contact Person: Ms. Anne Krey, Scientific Pository Administrator, DSP, 6100 Executive

Review Administrator, DSR, 6100 Executive Boulevard, Room 5E01, Bethesda, Maryland 20892, Telephone: 301–496–1485.

Purpose/Agenda: To evaluate and review research grant applications.

These meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The discussion of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. [93.864, Population Research and No. 93.865, Research for Mothers and Children], National Institutes of Health, HHS)